Pfizer Inc. (PFE) Free Cash Flow (FCF): $9.08B
The free cash flow (FCF) for Pfizer Inc. (PFE) is $9.08B. It is below its 12-month average by 4.01% ($9.46B).
PFE Free Cash Flow (FCF) Chart
PFE Average Free Cash Flow (FCF) Chart
PFE Current vs Average Free Cash Flow (FCF) Chart
PFE Free Cash Flow (FCF) Metrics
FREE CASH FLOW (FCF)
$9.08B
FREE CASH FLOW (FCF) AVG TTM
$9.46B
FREE CASH FLOW (FCF) AVG 3Y
$12.43B
FREE CASH FLOW (FCF) AVG 5Y
$15.20B
FREE CASH FLOW (FCF) AVG 10Y
$14.18B
FREE CASH FLOW (FCF) AVG 15Y
$14.49B
FREE CASH FLOW (FCF) AVG 20Y
$14.45B
CURRENT VS TTM AVG
-4.01%
CURRENT VS 3Y AVG
-27.01%
CURRENT VS 5Y AVG
-40.30%
CURRENT VS 10Y AVG
-36.01%
CURRENT VS 15Y AVG
-37.37%
CURRENT VS 20Y AVG
-37.18%
FCF Analysis
Free Cash Flow (TTM)
$9.08B
FCF Yield
6.45%
Price/FCF
15.5
Formula: FCF = Operating Cash Flow - Capital Expenditures
Why FCF matters:
- Shows actual cash available (not accounting earnings)
- Funds dividends, buybacks, and debt reduction
- Less susceptible to accounting manipulation than net income
- Key metric for DCF valuation models
Pfizer Inc. Free Cash Flow (FCF) Formula & Definition
Free Cash Flow represents the cash a company generates after accounting for capital expenditures. It's the cash available for dividends, buybacks, debt reduction, or reinvestment.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Free Cash Flow (FCF) FAQ
- What is the free cash flow (FCF) for Pfizer Inc. (PFE)?
- The free cash flow (FCF) for PFE stock is $9.08B.
- What is the TTM average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The TTM average free cash flow (FCF) for PFE stock is $9.46B.
- What is the 3Y average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The 3Y average free cash flow (FCF) for PFE stock is $12.43B.
- What is the 5Y average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The 5Y average free cash flow (FCF) for PFE stock is $15.20B.
- What is the 10Y average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The 10Y average free cash flow (FCF) for PFE stock is $14.18B.
- What is the 15Y average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The 15Y average free cash flow (FCF) for PFE stock is $14.49B.
- What is the 20Y average free cash flow (FCF) for Pfizer Inc. (PFE)?
- The 20Y average free cash flow (FCF) for PFE stock is $14.45B.
Pfizer Inc. Free Cash Flow (FCF) History
| DATE | FREE CASH FLOW (FCF) |
|---|---|
| 2025-12-31 | $9.08B |
| 2024-12-31 | $9.84B |
| 2023-12-31 | $4.79B |
| 2022-12-31 | $26.03B |
| 2021-12-31 | $29.87B |
| 2020-12-31 | $11.61B |
| 2019-12-31 | $9.99B |
| 2018-12-31 | $13.63B |
| 2017-12-31 | $14.25B |
| 2016-12-31 | $13.90B |
| 2015-12-31 | $13.02B |
| 2014-12-31 | $15.30B |
| 2013-12-31 | $16.30B |
| 2012-12-31 | $15.73B |
| 2011-12-31 | $18.58B |
| 2010-12-31 | $9.94B |
| 2009-12-31 | $15.38B |
| 2008-12-31 | $16.54B |
| 2007-12-31 | $11.47B |
| 2006-12-31 | $15.54B |
| 2005-12-31 | $12.63B |
| 2004-12-31 | $13.74B |
| 2003-12-31 | $9.10B |
| 2002-12-31 | $8.43B |
| 2001-12-31 | $7.06B |
| 2000-12-31 | $4.00B |
| 1999-12-31 | $1.50B |
| 1998-12-31 | $1.73B |
| 1997-12-31 | $686.00M |
| 1996-12-31 | $1.29B |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla